This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fournier, P. G.J. Articles by Clézardin, P. Search for Related Content PubMed PubMed Citation Articles by Fournier, P. G.J. Articles by Clézardin, P.

Lowering Bone Mineral Affinity of Bisphosphonates as a Therapeutic Strategy to Optimize Skeletal Tumor Growth Inhibition In vivo

¹ Institut National de la Santé et de la Recherche Médicale, Research Unit UMR 664, Faculté de Médecine Laennec, Lyon, France; ² Université Claude Bernard Lyon 1, Villeurbanne, France; ³ Institute of Medical Sciences, Aberdeen, United Kingdom; and ⁴ Procter and Gamble Pharmaceuticals, Mason, Ohio

Requests for reprints: Philippe Clézardin, Institut National de la Sante et de la Recherche Medicale, Research Unit UMR 664, Faculté de Médecine Laennec, Rue Guillaume Paradin, F-69372 Lyon, France. Phone: 33-4-78-78-57-37; Fax: 33-4-78-77-87-72; E-mail: philippe.clezardin{at}inserm.fr.

Key Words: breast cancer • bone metastasis • bisphosphonate • risedronate

Bisphosphonates bind avidly to bone mineral and are potent inhibitors of osteoclast-mediated bone destruction. They also exhibit antitumor activity in vitro. Here, we used a mouse model of human breast cancer bone metastasis to examine the effects of risedronate and NE-10790, a phosphonocarboxylate analogue of the bisphosphonate risedronate, on osteolysis and tumor growth. Osteolysis was measured by radiography and histomorphometry. Tumor burden was measured by fluorescence imaging and histomorphometry. NE-10790 had a 70-fold lower bone mineral affinity compared with risedronate. It was 7-fold and 8,800-fold less potent than risedronate at reducing, respectively, breast cancer cell viability in vitro and bone loss in ovariectomized animals. We next showed that risedronate given at a low dosage in animals bearing human B02-GFP breast tumors reduced osteolysis by inhibiting bone resorption, whereas therapy with higher doses also inhibited skeletal tumor burden. Conversely, therapy with NE-10790 substantially reduced skeletal tumor growth at a dosage that did not inhibit osteolysis, a higher dosage being able to also reduce bone destruction. The in vivo antitumor activity of NE-10790 was restricted to bone because it did not inhibit the growth of subcutaneous B02-GFP tumor xenografts nor the formation of B16-F10 melanoma lung metastases. Moreover, NE-10790, in combination with risedronate, reduced both osteolysis and skeletal tumor burden, whereas NE-10790 or risedronate alone only decreased either tumor burden or osteolysis, respectively. In conclusion, our study shows that decreasing the bone mineral affinity of bisphosphonates is an effective therapeutic strategy to inhibit skeletal tumor growth in vivo. [Cancer Res 2008;68(21):8945–53]

This article has been cited by other articles:

				F. P. Coxon An Update on the Pharmacology of Bisphosphonates and Analogues with Lower Bone Affinity IBMS BoneKEy, October 1, 2008; 5(10): 357 - 369. [Abstract] [Full Text] [PDF]